Overview
On 17 April 2007, orphan designation (EU/3/07/445) was granted by the European Commission to Gene Signal SAS, France, for antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for the prevention of corneal graft rejection.
Key facts
Active substance |
Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)
|
Intended use |
Prevention of corneal graft rejection
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/07/445
|
Date of designation |
17/04/2007
|
Sponsor |
Gene Signal SAS
4, rue Pierre Fontaine 91000 Evry France Telephone: + 33 1 55 60 12 55 Telefax: + 33 1 55 60 12 56 E-mail: salman.almahmood@wanadoo.fr |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: